Arrhythmic Risk Stratification in Cardiac Amyloidosis: A Review of the Current Literature

Area of Science:

• Cardiology
• Cardiovascular Research
• Infiltrative Cardiomyopathies

Background:

• Cardiac amyloidosis is the leading infiltrative heart disease, stemming from misfolded protein deposition.
• It causes heart failure, conduction disorders, and potentially fatal arrhythmias like atrial fibrillation and ventricular arrhythmia.
• Early diagnosis and management strategies for cardiac amyloidosis-related arrhythmias remain challenging.

Purpose of the Study:

• To review current evidence on arrhythmic risk stratification in cardiac amyloidosis.
• To discuss available and emerging therapeutic strategies for managing arrhythmias in these patients.
• To highlight unresolved issues in diagnosis and treatment.

Main Methods:

• Literature review of recent studies on cardiac amyloidosis and arrhythmias.
• Analysis of data on electrophysiological disturbances, risk stratification tools, and treatment outcomes.
• Synthesis of evidence regarding novel therapies and their impact on arrhythmia prevention.

Main Results:

• Extreme bradycardia is a primary cause of arrhythmic death; ventricular arrhythmias occur even in early stages.
• Atrial impairment increases AF risk, often resistant to treatment, and leads to recurrent thromboembolic events.
• Increasing diagnoses due to population aging and improved imaging necessitate updated management guidelines.

Conclusions:

• Effective risk stratification and timely intervention are crucial for preventing sudden cardiac death in cardiac amyloidosis.
• Current novel therapies aim to improve patient outcomes but require further evaluation for arrhythmia prevention.
• Further research is needed to optimize diagnosis and treatment strategies for arrhythmias in cardiac amyloidosis.